Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

22.01.2021 | short review | Ausgabe 1/2021 Open Access

memo - Magazine of European Medical Oncology 1/2021

Diagnosis and supportive therapeutic management of cardiac light chain amyloidosis—a cardiologist’s perspective

memo - Magazine of European Medical Oncology > Ausgabe 1/2021
MD Christina Binder, MD, PhD Franz Duca
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Cardiac amyloidosis is caused by deposition of abnormally folded proteins (amyloid). The most common forms of amyloidosis which present with cardiac involvement are light-chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). Even with novel treatments emerging, the prognosis of these patients remains poor once amyloid deposits in the heart. Therefore, knowledge on clinical and imaging features of cardiac amyloidosis is crucial to make an early diagnosis and improve patient outcomes. This article reviews the most important diagnostic findings of cardiac amyloidosis and gives an overview on the therapeutic management of these patients, including supportive-, device- and disease-specific drug therapies focusing on AL amyloidosis.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 1/2021

memo - Magazine of European Medical Oncology 1/2021 Zur Ausgabe